SCHEDULE A
FORM OF DRAWDOWN NOTICE
DRAWDOWN NOTICE
Drawdown
No. [ ]
dated
between
KREOS CAPITAL VII AGGREGATOR SCSP | BIOLINERX LTD. |
the (“Lender”) | the (“Borrower”) |
This Drawdown Notice forms a Schedule to a Loan Agreement between the Lender and the Borrower dated [ ] [ ] 2022 (the “Loan Agreement”)
The Lender has granted the Borrower a loan facility pursuant to the terms and conditions set out in the Loan Agreement and attached Schedules.
Words and expressions in this Drawdown Notice shall have the same meanings as in the Loan Agreement.
PART 1
Loan Details
Total Loan Facility | | US$ 40,000,000 |
Amount of Loan Facility to be drawn down pursuant to this Drawdown Notice | | [ ] |
Loan Term | | [ ] |
Bank Account Details for remittance of funds | | [ ] |
We confirm that:
(a) | the representations and warranties made by us in the Loan Agreement are true and accurate on the date of this Drawdown Notice as if made on such date; and |
(b) | no Event of Default has occurred and is continuing or would result from the delivery of this Drawdown Notice. |
for and on behalf of
[ ]
Authorized Signatory………………
Name ………………………………….
Dated [ ] 202[ ]
SCHEDULE B
LIST OF EQUIPMENT
SCHEDULE C
ACCOUNT RECEIVEBLES
SCHEDULE D
CUSTOMERS
SCHEDULE E
INTELLECTUAL PROPERTY
SCHEDULE F
INITIAL SECURITY DOCUMENTS
| 1. | Borrower – Debenture Fixed Charge; |
| 2. | Borrower – Debenture Floating Charge; |
| 3. | Borrower – US IP Security Agreement; |
| 4. | Subsidiary – Guarantee Agreement; |
SCHEDULE 1.41
PERMITTED INDEBTEDNESS
(a) Financial Indebtedness of Borrower in favor of the Lender arising under this Agreement or any associated documents including the Security Documents.
(b) Indebtedness of up to $500,000 in the aggregate incurred for financing the acquisition of new equipment (“Equipment Financing”).
(c) Other indebtedness not to exceed $500,000 at any time outstanding.
(d) Extensions, refinancing and renewals of any items of Permitted Indebtedness, provided that the principal amount is not increased or the terms modified.
(e) Accounting and other derivative based liabilities such as warrants and stock options.
(f) any right of the IIA pursuant to currently existing approved IIA programs of the Company.
SCHEDULE 1.42
PERMITTED SECURITY INTEREST
(a) Security Interests for taxes, fees, assessments or other governmental charges or levies; (b) Security Interests of up to $500,000 in the aggregate related to Equipment Financing, provided that the Security Interest shall be solely over the relevant purchased equipment; (c) those certain Security Interests granted in favor of Kreos Capital V (Expert Fund) LP, in connection with that certain Agreement for the Provision of a Loan Facility by and between Kreos Capital V (Expert Fund) LP and the Borrower dated October 2, 2018; (d) the rights of the Israeli Innovation Authority pursuant to applicable law and the terms of its grants with the Borrower; and (e) royalty payments to commercial partners, pursuant to applicable agreements.
SCHEDULE Schedule 3.5.1(iv)
CEO CERTIFICATE
SCHEDULE 3.5.1(xiv)
LEGAL OPINION
SCHEDULE 12.2.2
LIST OF INSURANCE POLICIES
The insurance policies listed below and any extension, expansion and/or replacement of such policies:
Duly executed by the parties on the date first set out on the first page of this Loan Agreement.
BORROWER
For and on behalf of
BIOLINE RX LTD.
By: /s/ Philip Serlin
Its: CEO
Date: September 14, 2022
LENDER
For and on behalf of
KREOS CAPITAL VII AGGREGATOR SCSP
By: /s/ Mark Collins
Its: Director
Date: September 14, 2022